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To date, estrogen is the only known endogenous
estrogen receptor (ER) ligand that promotes ER+
breast tumor growth. We report that the cholesterol
metabolite 27-hydroxycholesterol (27HC) stimulates
MCF-7 cell xenograft growth in mice. More impor-
tantly, in ER+ breast cancer patients, 27HC content
in normal breast tissue is increased compared to
that in cancer-free controls, and tumor 27HC content
is further elevated. Increased tumor 27HC is corre-
lated with diminished expression of CYP7B1, the
27HCmetabolizing enzyme, and reduced expression
of CYP7B1 in tumors is associated with poorer
patient survival. Moreover, 27HC is produced by
MCF-7 cells, and it stimulates cell-autonomous,
ER-dependent, and GDNF-RET-dependent cell pro-
liferation. Thus, 27HC is a locally modulated, non-
aromatized ER ligand that promotes ER+ breast
tumor growth.INTRODUCTION
Breast cancer is second most common malignancy in women
behind skin cancer, with 1 million new cases diagnosed world-
wide each year (McPherson et al., 2000). Estrogen receptor
(ER) a-induced signal transduction controls the growth of a
majority of breast cancers (Jensen and Jordan, 2003), and the
risk of ER+ breast cancer is greatest in postmenopausal women
(Patel et al., 2007). Endocrine-based therapies against ER+
breast cancers antagonize ER function (e.g., with synthetic
selective estrogen receptor modulators [SERMs] including
tamoxifen) or inhibit estrogen biosynthesis (e.g., with aromatase
inhibitors) (Patel et al., 2007). However, initial resistance toCearomatase inhibition is frequent, with early response rates of
only 20%–50%, and there is also acquired resistance. As such,
there may be important estrogen-independent, ER-mediated
processes promoting ER+ tumor growth that are unhindered
by aromatase inhibition (Chen et al., 2006).
We previously identified the cholesterol metabolite 27-hydrox-
ycholesterol (27HC) as an endogenous SERM (DuSell et al.,
2008; Umetani et al., 2007). In the present work, we determined
how 27HC impacts ER+ breast cancer in vivo in mice and ER+
breast cancer risk in women. In addition, we addressed the
following questions: (1) What in vivo mechanisms govern 27HC
levels in breast tumors? (2) What are the roles of sterol
27-hydroxylase (CYP27A1) and oxysterol 7a-hydroxylase
(CYP7B1), which synthesize and metabolize 27HC, respectively
(Russell, 2003)? and (3) How does 27HC stimulate ER+ breast
cancer cell growth?
RESULTS
27HC Promotes ER+ Breast Tumor Growth
The capacity of 27HC to stimulate ER+ breast cancer cell prolif-
eration was evaluated in MCF-7 cells by quantifying bromodeox-
yuridine (BrdU) or 3H-thymidine incorporation. With an effect
comparable to E2, 27HC promoted MCF-7 cell growth (Fig-
ure 1A). In healthy humans, plasma 27HC concentration is
0.22–0.60 mM and 50%–90% of 27HC is esterified (Dzeletovic
et al., 1995; Li-Hawkins et al., 2000; Umetani et al., 2007);
thus, unesterified plasma levels approximate 108M, and
108M was the threshold concentration for activation of MCF-7
cell proliferation (Figure 1B). The impact of other oxysterols
was also evaluated (Figure S1), and MCF-7 cell proliferation
was modestly stimulated by 25-hydroxycholesterol, which alters
ER function but not as potently as 27HC and was previously
shown to activate ERa-mediated signaling in cancer cells
(Umetani et al., 2007; Lappano et al., 2011). 22R-hydroxycholes-
terol, which inhibits E2 activation of either ERa or ERb, andll Reports 5, 637–645, November 14, 2013 ª2013 The Authors 637
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Figure 1. 27HC Promotes MCF-7 Cell and
Ishikawa Cell Proliferation, and In Vivo
27HC Stimulates MCF-7 Cell Xenograft
Growth and an Uterotrophic Response
(A–D) Cell proliferation was evaluated by quanti-
fying BrdU (A) or 3H-thymidine incorporation (B–D),
n = 4–8. (A) Growth responses of MCF-7 cells to E2
(108M) or 27HC treatment (108 to 106M) for
24 hr were compared. (B) The dose response of
MCF-7 cells to 27HC (109 to 106M, for 24 hr) was
determined. (C) The requirement for ERa in the
growth response of MCF-7 cells to E2 (10
8M) or
27HC (106M) was evaluated in cells treated with
methyl-piperidino-pyrazole (MPP, 10 mM) for 24 hr.
(D) Growth responses of Ishikawa cells to E2
(108M) or 27HC treatment (108 to 106M) for
24 hr were compared.
(E) MCF-7 cell xenograft growth was compared in
SCID mice treated with vehicle, 27HC, or E2 for
28 days. Representative tumors are shown.
(F) Tumor weights at end of study (n = 9–10).
(G) Uterine weight/body weight ratio in mice
treated for 28 dayswith vehicle, E2, or 27HC (n = 6).
*p < 0.05 versus vehicle, yp < 0.05 versus no MPP.
All values shown are mean ± SEM. See also
Figures S1, S2, and S3.7-ketocholesterol, which does not bind to ER (Umetani et al.,
2007), did not promote MCF-7 cell proliferation. 27HC also stim-
ulated proliferation in three other ER+ breast cancer cell lines,
HCC1428, T47D, and ZR75, indicating that the response is not
unique to MCF-7 cells (Figure S2). MCF-7 cells express both
ERa and liver X receptors (LXR) (DuSell et al., 2008; El Roz
et al., 2012), and 27HC is a ligand for both receptors (Janowski
et al., 1999; Umetani et al., 2007). To evaluate whether LXR acti-
vation stimulates MCF-7 cell growth, the impact of the LXR
agonist T1317 was determined. In contrast to 27HC (Figures
1A and 1B), the LXR agonist T1317 caused a decline in MCF-7
cell proliferation (Figure S3). This finding mirrors prior observa-
tions that, whereas ER activation stimulates ERa+ breast cancer
cell growth, LXR activation is inhibitory (El Roz et al., 2012; Vedin
et al., 2009). A requirement for ERa in 27HC action on MCF-7
cells was then demonstrated by the finding that both E2- and
27HC-induced cell proliferation was prevented by the selective
ERa antagonist methyl-piperidino-pyrazole (MPP, 10 mM) (Fig-
ure 1C) (Sun et al., 2002). These results expand upon our prior
work on 27HC and MCF-7 cell proliferation, which did not reveal638 Cell Reports 5, 637–645, November 14, 2013 ª2013 The Authorsthe operative receptor or growth-related
responses to less than 106 M 27HC
(DuSell et al., 2008); it is now apparent
that at physiologic levels the oxysterol
stimulates MCF-7 cell growth via ERa.
In addition to MCF-7 and other ER+
breast cancer cell lines, studies were
performed with the human endometrial
Ishikawa cell line that provides a cell-
culture model of endometrial cancer
(Vollmer, 2003). With an effect equal to
that of E2, 27HC stimulated Ishikawa cell
growth (Figure 1D). Thus, the proliferativeresponse to 27HC is not unique to breast cancer, and the growth
of another sex-steroid-responsive malignancy is also enhanced
by the oxysterol.
To determine how 27HC impacts ER+ breast tumor growth
in vivo, MCF-7 cell xenografts were studied in ovariectomized
female SCID mice. Following tumor establishment with E2,
mice received vehicle, 27HC, or E2 for 4 weeks, and tumors
were harvested (Figure 1E). Tumor weight was increased 73%
by 27HC and 173% by E2 (Figure 1F). Thus, 27HC stimulates
ER+ breast tumor growth in vivo.
To evaluate an additional estrogen-sensitive tissue, the effects
of 27HC on the uterus were determined in ovariectomized mice
(Figure 1G). E2 and 27HC caused equivalent 2.4- and 2.6-fold
increases in uterine weight, providing further evidence that
27HC is a growth-promoting ER ligand in vivo.
27HC Is Abundant in Normal Breast Tissue and in ER+
Tumors from Cancer Patients
The potential impact of 27HC on ER+ breast cancer in women
was then investigated. Women with ERa(+) breast cancer and
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Figure 2. 27HC Content Is Increased in
Normal Breast Tissue and Tumors from
ER+ Breast Cancer Patients, and It Is
Locally Modulated
(A and B) Serum 27HC (A) and total cholesterol
concentration (B) in control and breast cancer
patients (n = 17 and 58, respectively). Values for
ten cancer patients with serum 27HC greater than
2SD above the mean value for controls are shown
in red.
(C and D) Relationship of serum 27HC to serum
cholesterol concentration in controls (C, n = 17)
and cancer patients (D, n = 58).
(E) 27HC content in normal breast tissue from
controls (n = 17) and cancer patients (n = 48) and in
tumors (n = 32). *p < 0.05 versus control, yp < 0.05
versus cancer patient normal breast.
(F and G) Relationship of normal breast 27HC
content to serum 27HC in controls (F, n = 17) and
cancer patients (G, n = 40).
(H and I) Relationship of tumor 27HC content to
serum 27HC (H) or normal breast 27HC content (I)
in cancer patients (n = 27).
See also Figure S4.age- and race-matched cancer-free subjects were recruited
from the UT Southwestern Center for Breast Care (n = 66 and
18, respectively). Clinical parameters for the two groups are
shown in Table S1. At presentation, mean serum 27HC levels
were comparable in the two groups (Figure 2A). Interestingly,
there was a broader range of serum 27HC in cancer patients,
with ten subjects having levels greater than 2SD above theCell Reports 5, 637–645, Nmean for controls (red values in Figures
2A and 2B). Mean total serum cholesterol
levels were also similar in the two study
groups (Figure 2B). Notably, of the ten
cancer patients with elevated circulating
27HC compared to controls, only one
had hypercholesterolemia. Because
27HC is a cholesterol metabolite trans-
ported in the same lipoprotein particles
as cholesterol, there was a predictable
positive association between serum
27HC and cholesterol in both controls
and cancer patients (Figures 2C and
2D). However, whereas the amount of
variability in serum 27HC that was related
to cholesterol in controls was 40%, it was
only 18% in cancer patients. These find-
ings suggest that processes governing
27HC synthesis from cholesterol or
27HC metabolism may be altered in a
subset of womenwith ER+ breast cancer.
27HC was then quantified in normal
breast tissue and in tumors (Figure 2E).
There were insufficient amounts of
samples to also measure estrogen con-
tent. Compared to controls, there was
3-fold greater 27HC in normal breasttissue from cancer patients, and tumor content was further
elevated by 2.3-fold. Possible relationships between breast
tissue 27HC content and either serum 27HC (Figures 2F and
2G) or serum cholesterol were assessed (Figures S4A and
S4B), and none was found. In addition, in cancer patients no
relationships were observed between tumor 27HC content and
either serum 27HC or normal breast tissue 27HC (Figures 2Hovember 14, 2013 ª2013 The Authors 639
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and 2I). These findings indicate that 27HC abundance in the
breast and in ER+ tumors is not governed by circulating
levels of the oxysterol or its substrate, but instead by local
mechanisms.
CYP7B1 Expression Is Diminished in ER+ Tumors and
Predictive of Overall Survival
To determine if breast cancer cells possess the molecular
machinery required to regulate 27HC abundance, CYP27A1
and CYP7B1 expression were evaluated in 31 breast cancer
cell lines (Figure 3A). CYP27A1 and CYP7B1 transcripts were
detected in the majority of the cell lines, at varying levels. Having
determined that neither circulating concentrations of 27HC nor
its precursor influence 27HC levels in ER+ breast tumors (Fig-
ure 2), we next compared CYP27A1 and CYP7B1 expression
in 406 ER+ tumors versus 63 normal breast tissue samples in
The Cancer Genome Atlas (TCGA) (2012). CYP27A1 expression
was similar in normal breast and ER+ tumors (Figure 3B). In
contrast, CYP7B1 expression was decreased by 50% in ER+
tumors compared with normal breast tissue (Figure 3C). As
such, the elevation in 27HC found in ER+ tumors is not related
to an increase in the synthesizing enzyme CYP27A1 but instead
to a loss of 27HC metabolism by CYP7B1.
We next determined how a decline in the ability to metabolize
27HC impacts ER+ breast cancer cell growth (Figure 3D). In the
absence of exogenous 27HC, small interfering RNA (siRNA)
knockdown of CYP7B1 caused a 78% increase in MCF-7 cell
proliferation. Furthermore, whereas 27HC treatment of control
cells stimulated growth to levels observed with CYP7B1 dele-
tion, there was no additional proliferation with 27HC in cells
deficient in CYP7B1. These findings indicate that ER+ breast
cancer cells synthesize 27HC, which promotes replication in a
cell-autonomous manner, and that such replication is enhanced
if CYP7B1 is deficient. Further evidence of 27HC-induced
cell-autonomous growth is provided by the finding that the
increase in MCF-7 cell proliferation with CYP7B1 knockdown
is prevented by ERa antagonism with MPP (Figure 3E). In intact
tumors, stromal cells may be an additional local source of 27HC,
because macrophages express the 27HC-synthesizing enzyme
CYP27A1 and generate 27HC (Hansson et al., 2003).
Having found that relative CYP7B1 expression influences ER+
breast cancer cell replication, how tumor CYP7B1 expression
impacts overall patient outcome was queried using the TCGA
data set. Kaplan-Meier curves were generated for cancer
patients in the lowest versus highest quartiles for tumor
CYP7B1 or CYP27A1 expression. Whereas overall survival
curves were similar for patients with low versus high tumorFigure 3. Breast Cancer Cells Express CYP27A1 and CYP7B1 and Di
CYP7B1 Expression Is Diminished in ER+ Tumors and Predictive of Ov
(A) CYP27A1 and CYP7B1 transcript abundance was evaluated in 31 breast c
expression is defined relative to the median expression level of all genes on the
(B and C) Expression of CYP27A1 and CYP7B1 were compared in 63 normal brea
the bean plots shown, each short black line is a sample, the long black line is th
(D and E) Cell proliferation was compared in control siRNA-transfected MCF-7 c
presence of 27HC (108 to 106M) for 24 hr (D), or in the absence or presence of M
versus control siRNA, yp < 0.05 versus no 27HC or no MPP.
(F and G) Kaplan-Meier curves for TCGA ER+ breast cancer patients in the highe
See also Figure S6A.
CeCYP27A1 abundance (Figure 3F), survival was markedly poorer
for patients with low versus high tumor CYP7B1 expression (Fig-
ure 3G). Multivariate Cox regression modeling further revealed
that low CYP7B1 expression continues to be associated with
poor overall survival outcome (HR = 7.28 and p = 0.00178)
even after adjusting for the effects of age, tumor size, nodal
status, and perioperative therapy (Table S2). Thus, the prognosis
for ER+ breast cancer is predicted by processes in the tumor that
govern 27HC metabolism.
27HC Target Genes Promote ER+ Breast Cancer Growth
Now knowing that diminished CYP7B1 expression enhances
ER+ breast cancer cell proliferation, and that in parallel it
adversely impacts clinical outcome, potentially operative target
genes of 27HC were identified by comparing gene expression
in CYP7B1-low versus CYP7B1-high tumors in TCGA. Using a
false discovery rate of <0.001, 3,233 genes were downregulated
in CYP7B1-low versus CYP7B1-high tumors, and 1,026 genes
were upregulated (Figure 4A). Considering only probes with
high expression level variance (fold change >2 or <1/2), there
were 569 downregulated genes and 14 upregulated genes in
CYP7B1-low versus CYP7B1-high tumors (Figure 4B). Gene
set enrichment analysis further revealed that genes associated
with breast cancer and other malignancies are highly enriched
in CYP7B1-low breast tumors (Table S3).
The 14 upregulated genes in CYP7B1-low versus CYP7B1-
high tumors (Table S4), which are therefore upregulated under
conditions in which 27HC is elevated, include genes implicated
in ER-driven cancers and ERa itself. 27HC modulation of four
of these genes was tested in MCF-7 cells. C6orf211 is an open
reading frame immediately upstream of the ERa gene whose
silencing in MCF-7 blunts proliferation (Dunbier et al., 2011).
PARD6B (par-6 partitioning defective 6 homolog-b) is a SRC-3
and ER target gene implicated in cell transformation (Labhart
et al., 2005; Qiu et al., 2000). The receptor tyrosine kinase RET
and its coreceptor GFRa1 (GDNF family a-receptor-1) are upre-
gulated in a subset of ER+ breast cancers, and GDNF-RET
signaling is a major determinant of the response to and develop-
ment of resistance to aromatase inhibition (Morandi et al., 2011).
Mirroring E2 action, 27HC caused 1.9- to 2.3-fold increases in
C6orf211, PARD6B, GFRa1, and RET expression (Figures
4C–4F). The impact of 27HC on GDNF expression was also
determined, and it increased expression of the ligand by
2.4-fold (Figure 4G). In contrast to 27HC and consistent with a
lack of stimulation of MCF-7 cell proliferation, LXR activation
by T1317 did not upregulate GFRa1 or RET expression in
MCF-7 cells, and GDNF expression was increased by onlysplay Cell-Autonomous 27HC-Driven, ERa-Dependent Growth, and
erall Survival
ancer cell lines. Heatmap shows absolute expression, and low versus high
array.
st samples and 406 ER+ breast tumors in The Cancer Genome Atlas (TCGA). In
e mean, and the shape of the bean reveals the distribution of the samples.
ells and in cells transfected with siRNA targeting CYP7B1, in the absence or
PP (10 mM) for 24 hr (E). In (D) and (E), values are mean ± SEM, n = 4, *p < 0.05
st versus lowest quartiles for tumor CYP27A1 (F) or CYP7B1 (G).
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20% (Figures S5A–S5C). Participation of GDNF-RET signaling in
27HC-induced cell proliferation was then evaluated by silencing
RET (Figure 4H). Whereas 27HC stimulated proliferation in
control cells, it had no impact on RET-depleted cells. Thus,
numerous genes are modulated by 27HC in ER+ breast cancer,
these include components of GDNF-RET signaling, and the latter
are critically involved in 27HC-induced cancer cell proliferation.
DISCUSSION
To date estrogenhas been the only known endogenous ER ligand
that promotes ER+ breast tumor growth. Because resistance to
aromatase inhibition is common and often evident at treatment
initiation (Chen et al., 2006), other ER-mediated mechanisms
may be operative in disease pathogenesis. We have discovered
that the cholesterol metabolite 27HC stimulatesMCF-7 cell xeno-
graft growth inmice. Inparallel,wehave shown that, inER+breast
cancer patients, 27HC content in normal breast tissue is
increased compared to cancer-free controls, and that tumor
27HC abundance is further elevated. We have also determined
in women that neither normal breast nor tumor 27HC content
are influenced by circulating levels of 27HC or its precursor, and
that increases in tumor 27HC are instead related to diminished
expression of the 27HC metabolizing enzyme CYP7B1. These
collective findings reveal that 27HC is a locally modulated, nonar-
omatized ER ligand that promotes ER+ breast cancer growth.
There are three clinical conditions inwhich 27HC abundance is
elevated. The first is during the postmenopausal period. Serum
27HC levels increase in women after menopause (Burkard
et al., 2007), and this may be related to estrogen deprivation
because in mice E2 upregulates hepatic CYP7B1 expression in
an ERa-dependent manner without impacting CYP27A1 (Yama-
moto et al., 2006), and it lowers serum 27HC (T.I. and M.U.,
unpublished data). 27HC abundance is also predictably elevated
in the setting of hypercholesterolemia (Brown and Jessup, 1999;
Umetani et al., 2007), and with obesity, which is frequently a
comorbidity with hypercholesterolemia (Lerman et al., 2005;
Reaven, 2005). In mice, a high-fat, high-cholesterol western
diet elevates serum 27HC by 2- to 3-fold (T.I. and M.U., unpub-
lished data). In women, both dyslipidemia and obesity raise
breast cancer risk and severity, with obesity particularly having
an adverse impact in postmenopausal women (Bianchini et al.,
2002; Calle et al., 2003; Furberg et al., 2004; Michalaki et al.,
2005), and breast cancer promotion by hypercholesterolemia
or obesity has been demonstrated in animal models (Llaverias
et al., 2011; Nunez et al., 2008). Notably, epidemiologic studies
indicate that in women obesity affects only ER+ breast cancers
(Althuis et al., 2004), and similarly in mice only ER+ breast cancer
models display greater tumor growth with obesity (Cleary et al.,Figure 4. 27HC Modulates Gene Expression in ER+ Breast Cancer and
(A and B) Gene expression was compared in TCGA ER+ breast tumors in the hig
Using SAMR analysis and a false discovery rate of <0.001, 3,233 genes were dow
upregulated. (B) Heatmap of the 583 differentially expressed (DE) genes with h
CYP7B1 low and high groups are noted above the heatmap in black and red, re
(C–G) Effect of E2 (10
9M) versus 27HC (106M) on MCF-7 cell expression of C6
(H) The effect of 27HC (108 to 106M for 24 hr) on MCF-7 cell proliferation was
In (C)–(H), values shown are mean ± SEM, n = 8, *p < 0.05 versus vehicle. See a
Ce2010; Gu et al., 2011; Nunez et al., 2008). Although the basis by
which menopause, hypercholesterolemia and obesity promote
ER+ breast cancer is multifaceted (Cleary et al., 2010; Gu
et al., 2011), 27HC should now be considered as a potentially
critical pathogenetic factor.
Our discovery of 27HC as the second endogenous ER ligand
that promotes ER+ breast tumor growth has important clinical
implications. Because estrogen upregulates CYP7B1 (Tang
et al., 2008; Yamamoto et al., 2006) and lowers 27HC as noted
above, either tamoxifen treatment or aromatase inhibition may
increase the abundance of the second oncogenic ER ligand. In
addition, 27HC is a nonaromatized molecule whose synthesis
is unaffected by aromatase inhibition. As such, assessments of
tumor CYP7B1 expression or 27HC content may provide a
potentially critical means to personalize hormone-based
therapy. Furthermore, lowering 27HC abundance may represent
a key strategy for combating a subset of ER+ breast cancers.
Just as important is the finding that low tumor CYP7B1 is asso-
ciated with poorer ER+ breast cancer patient survival, such that
the evaluation of tumor CYP7B1 or 27HC abundance may also
have prognostic value.
Now knowing that CYP7B1 influences ER+ breast cancer
pathogenesis and prognosis, studies of potential somatic muta-
tions of the gene are warranted. At the same time, because
endometrial cancer cell growth is also promoted by 27HC, the
oxysterol and its regulatory enzymes deserve interrogation in
other steroid hormone-responsive cancers. Through such efforts
the cancer-promoting capacity of 27HC will be better under-
stood, and this may lead to further optimization of the prevention
and treatment of ER-dependent cancers.
EXPERIMENTAL PROCEDURES
Detailed experimental information is provided in the Supplemental Experi-
mental Procedures.
Cell Culture, Gene Silencing, and Assessments of Gene Expression
Studies were performed in MCF-7, HCC1428, T47D, ZR75-1, and Ishikawa
cells. In MCF-7, CYP7B1 or RET were deleted using siRNA-based strategies.
Potential 27HC or LXR target genes were evaluated by quantitative RT-PCR.
In all cell-culture studies, findings were confirmed in three independent
experiments.
Cell Proliferation
Cell proliferation was assessed by quantifying 3H-thymidine or BrdU incorpo-
ration. The role of ERa in cell proliferation was queried using the highly
selective antagonist MPP (Sun et al., 2002).
Orthotopic Breast Tumor Xenograft Model
Experiments approved by the Institutional Animal Care and Use Committee at
UT Southwestern were performed in female SCID mice as previouslyThereby Promotes Cancer Cell Growth
hest versus lowest quartiles for tumor CYP7B1 expression (n = 102/group). (A)
nregulated in CYP7B1-low versus CYP7B1-high tumors, and 1,026 genes were
igh expression level variance between the two CYP7B1 expression groups.
spectively.
orf211 (C), PARD6B (D), GFRa1 (E), RET (F), and GDNF (G).
compared in cells transfected with control siRNA versus siRNA targeting RET.
lso Figures S5A–S5C and S6B.
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described (Chambliss et al., 2010). Following MCF-7 xenograft establishment
with E2, mice received every-other-day injections of vehicle, 27HC (100 mg), or
E2 (6 mg) for 28 days, and tumors were harvested and weighed.
Control and Breast Cancer Patient Enrollment
Human benign breast tissue and primary breast tumors were obtained from
the UT Southwestern Tissue Repository under institutional-review-board-
approved studies.
27HC and Cholesterol Quantification
27HC was quantified in serum and tissue samples using high-pressure liquid
chromatography-mass spectrometry (McDonald et al., 2012), and total serum
cholesterol was measured as previously described (Zhang et al., 2012).
Breast Cancer Cell Line Gene Expression
CYP27A1 and CYP7B1 expression were evaluated in breast cancer cell lines
using Affymetrix GeneChips (http://www.affymetrix.com).
Tumor Gene Expression and Prognosis
Using The Cancer Genome Atlas (TCGA) (http://www.cancergenome.nih.gov),
expression levels of CYP27A1, and CYP7B1 were compared in normal breast
samples and ER+ breast tumors. In tumor samples, differences in gene
expression and in overall patient outcome were then compared in the highest
versus lowest CYP27A1 or CYP7B1 expression quartiles.
Statistical Analysis
Comparisons were made between multiple groups by analysis of variance
(ANOVA) with Neuman-Keuls post hoc testing.When indicated, nonparametric
ANOVA (Kruskal-Wallace) and post hoc Dunn testing was performed. Signifi-
cance was defined as p < 0.05. All values shown are mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.10.006.
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